Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Johnston

Showing results (101-110 of 136) with videos related to

Pageof 14
Sort By:
NPJ Breast Cancer|December 28, 2018
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacyAngelo Di Leo, Joyce O'Shaughnessy, George W Sledge, et al.
The Oncologist|June 15, 2020
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast CancerMatthew P Goetz, Miguel Martin, Eriko Tokunaga, et al.
Bioorganic & Medicinal Chemistry Letters|October 25, 2011
Identification of small-molecule inhibitors of Trypansoma cruzi replicationAndrew R Germain, Leigh C Carmody, Chris Dockendorff, et al.
Respiration; International Review of Thoracic Diseases|July 29, 2025
Comparison of Diagnostic Bronchoscopy Single-Arm Trials Using an Advanced Optimization Approach for Indirect Comparisons with Partial Individual Patient DataAnil Vachani, Septimiu Murgu, Fabien Maldonado, et al.
Breast Cancer Research and Treatment|August 17, 2022
Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospitalNiamh Cunningham, Scott Shepherd, Kabir Mohammed, et al.
NPJ Breast Cancer|January 25, 2019
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerStephen Johnston, Miguel Martin, Angelo Di Leo, et al.
Elife|July 14, 2021
AAV ablates neurogenesis in the adult murine hippocampusStephen Johnston, Sarah L Parylak, Stacy Kim, et al.
Breast Cancer Research and Treatment|March 29, 2013
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancerJohn M S Bartlett, Roger A'hern, Tammy Piper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2020
A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast CancerAleix Prat, Yi-Hsuan Tsai, Tomás Pascual, et al.
Breast (Edinburgh, Scotland)|October 3, 2017
Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experienceBelinda Kingston, Hamzeh Kayhanian, Chloe Brooks, et al.
Pageof 14

Showing results (101-110 of 136) with videos related to

Sort By:
Pageof 14
NPJ Breast Cancer|December 28, 2018
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacyAngelo Di Leo, Joyce O'Shaughnessy, George W Sledge, et al.
The Oncologist|June 15, 2020
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast CancerMatthew P Goetz, Miguel Martin, Eriko Tokunaga, et al.
Bioorganic & Medicinal Chemistry Letters|October 25, 2011
Identification of small-molecule inhibitors of Trypansoma cruzi replicationAndrew R Germain, Leigh C Carmody, Chris Dockendorff, et al.
Respiration; International Review of Thoracic Diseases|July 29, 2025
Comparison of Diagnostic Bronchoscopy Single-Arm Trials Using an Advanced Optimization Approach for Indirect Comparisons with Partial Individual Patient DataAnil Vachani, Septimiu Murgu, Fabien Maldonado, et al.
Breast Cancer Research and Treatment|August 17, 2022
Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospitalNiamh Cunningham, Scott Shepherd, Kabir Mohammed, et al.
NPJ Breast Cancer|January 25, 2019
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerStephen Johnston, Miguel Martin, Angelo Di Leo, et al.
Elife|July 14, 2021
AAV ablates neurogenesis in the adult murine hippocampusStephen Johnston, Sarah L Parylak, Stacy Kim, et al.
Breast Cancer Research and Treatment|March 29, 2013
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancerJohn M S Bartlett, Roger A'hern, Tammy Piper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2020
A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast CancerAleix Prat, Yi-Hsuan Tsai, Tomás Pascual, et al.
Breast (Edinburgh, Scotland)|October 3, 2017
Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experienceBelinda Kingston, Hamzeh Kayhanian, Chloe Brooks, et al.
Pageof 14